Ambu（547A）株式概要医療技術会社であるAmbu A/Sは、世界中の病院、診療所、救助隊に医療機器を開発、製造、販売している。 詳細547A ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長4/6過去の実績5/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より54.9%で取引されている 収益は年間22.96%増加すると予測されています 過去1年間で収益は28.9%増加しました リスク分析547A リスクチェックを通過した。すべてのリスクチェックを見る547A Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW500,622 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG500,622 investors already sharing narrativesYour Fair Value€Current Price€8.7827.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-65m10b2016201920222025202620282031Revenue DKK 10.1bEarnings DKK 787.4mAdvancedSet Fair ValueView all narrativesAmbu A/S 競合他社Carl Zeiss MeditecSymbol: XTRA:AFXMarket cap: €2.5bOttobock SE KGaASymbol: XTRA:OBCKMarket cap: €3.5bDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.5bEckert & ZieglerSymbol: XTRA:EUZMarket cap: €991.8m価格と性能株価の高値、安値、推移の概要Ambu過去の株価現在の株価DKK 8.7852週高値DKK 14.5252週安値DKK 7.76ベータ1.361ヶ月の変化0.52%3ヶ月変化-3.09%1年変化-33.62%3年間の変化-39.65%5年間の変化-71.30%IPOからの変化-70.48%最新ニュースお知らせ • Nov 07Ambu A/S announces Annual dividend, payable on December 08, 2025Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025.お知らせ • Oct 01Ambu A/S, Annual General Meeting, Dec 02, 2026Ambu A/S, Annual General Meeting, Dec 02, 2026.お知らせ • Sep 30+ 3 more updatesAmbu A/S to Report Q1, 2026 Results on Feb 04, 2026Ambu A/S announced that they will report Q1, 2026 results on Feb 04, 2026お知らせ • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.お知らせ • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).お知らせ • Nov 08Ambu A/S Proposes DividendThe Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year.最新情報をもっと見るRecent updatesお知らせ • Nov 07Ambu A/S announces Annual dividend, payable on December 08, 2025Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025.お知らせ • Oct 01Ambu A/S, Annual General Meeting, Dec 02, 2026Ambu A/S, Annual General Meeting, Dec 02, 2026.お知らせ • Sep 30+ 3 more updatesAmbu A/S to Report Q1, 2026 Results on Feb 04, 2026Ambu A/S announced that they will report Q1, 2026 results on Feb 04, 2026お知らせ • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.お知らせ • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).お知らせ • Nov 08Ambu A/S Proposes DividendThe Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year.Reported Earnings • Nov 06Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023)Full year 2024 results: EPS: kr.0.88 (up from kr.0.65 in FY 2023). Revenue: kr.5.39b (up 13% from FY 2023). Net income: kr.235.0m (up 40% from FY 2023). Profit margin: 4.4% (up from 3.5% in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Oct 01+ 3 more updatesAmbu A/S, Annual General Meeting, Dec 03, 2025Ambu A/S, Annual General Meeting, Dec 03, 2025.お知らせ • Sep 30Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025Ambu A/S announced that they will report Q1, 2025 results on Jan 30, 2025Reported Earnings • Sep 01Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023)Third quarter 2024 results: EPS: kr.0.50 (up from kr.0.19 in 3Q 2023). Revenue: kr.1.38b (up 16% from 3Q 2023). Net income: kr.134.0m (up 163% from 3Q 2023). Profit margin: 9.7% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Reported Earnings • May 15Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023)Second quarter 2024 results: EPS: kr.0.54 (up from kr.0.06 in 2Q 2023). Revenue: kr.1.37b (up 15% from 2Q 2023). Net income: kr.144.0m (up kr.129.0m from 2Q 2023). Profit margin: 11% (up from 1.3% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year.Reported Earnings • Jan 31First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.1.25b (up 11% from 1Q 2023). Net income: kr.92.0m (up 318% from 1Q 2023). Profit margin: 7.3% (up from 1.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.お知らせ • Jan 30+ 1 more updateAmbu A/S Maintains Earnings Guidance for the Full-Year 2023/24Ambu A/S maintained earnings guidance for the Full-Year 2023/24. For the period,company expects Organic revenue growth of 7%-10%, EBIT margin before special items of 8%-10%.お知らせ • Dec 14Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of DirectorsAmbu A/S at its Annual General Meeting held on December 13, 2023, elected Shacey Petrovic as Vice Chair of the Board of Directors.お知らせ • Nov 18Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of DirectorsAmbu A/S at the Annual General Meeting to be held on 13 December 2023 Henrik Ehlers Wulff has decided not to run for re-election for Board of Directors.お知らせ • Nov 09Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23.お知らせ • Oct 12+ 1 more updateAmbu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024Ambu A/S has appointed Henrik Skak Bender as the company’s new Chief Financial Officer and member of the Executive Management, effective 1 January 2024. Henrik succeeds Thomas Frederik Schmidt, who will step down, effective 31 December 2023. During the past 20 years, Henrik has worked at leading international companies, such as was Audiology, Urban Partners, McKinsey & Co and A.P. Moller-Maersk. At the hearing aid company, was Audiology, he served as CFO and Head of Integration, leading the finance, IT, legal and procurement functions. Prior to that, he served as CFO at Widex, where he was responsible for developing and executing the company’s growth and transformation strategy, together with the rest of the management team. Most recently, Henrik joins from the asset management company, Urban Partners, where he serves as a member of the executive management, leading the company to grow from a Nordic player with EUR 6bn in assets under management in 2020 to a Northern European player with EUR +20bn in assets under management. At Urban Partners, Henrik held a position as Partner and COO, where he focused on driving and scaling a wide range of functions, including Investor Relations, Finance, IT and Sustainability.お知らせ • Sep 30+ 4 more updatesAmbu A/S to Report Q2, 2024 Results on May 14, 2024Ambu A/S announced that they will report Q2, 2024 results on May 14, 2024お知らせ • Sep 01+ 1 more updateAmbu A/S Narrows Earnings Guidance for the Full-Year 2022/23Ambu A/S narrowed earnings guidance for the full-year 2022/23. For the year, the company expected organic revenue growth guidance to 6%-8%, previously 5%-8%; EBIT margin before special items: 5-6% (maintained as per 10 July 2023).Reported Earnings • Sep 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr.1.20b (up 5.9% from 3Q 2022). Net income: kr.51.0m (up 82% from 3Q 2022). Profit margin: 4.3% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.お知らせ • Jul 12Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%).Reported Earnings • May 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.1.19b (up 6.0% from 2Q 2022). Net income: kr.15.0m (down 91% from 2Q 2022). Profit margin: 1.3% (down from 16% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year.Reported Earnings • Feb 08First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)First quarter 2023 results: EPS: kr.0.09 (up from kr.0.08 in 1Q 2022). Revenue: kr.1.13b (up 9.8% from 1Q 2022). Net income: kr.22.0m (up 10.0% from 1Q 2022). Profit margin: 1.9% (in line with 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Feb 07Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023Ambu A/S provided earnings guidance for the financial year of 2022-2023. For the year, the company expected organic revenue growth is 5% to 8%.Board Change • Nov 22High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Susanne Larsson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 16Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.4.44b (up 11% from FY 2021). Net income: kr.93.0m (down 62% from FY 2021). Profit margin: 2.1% (down from 6.2% in FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.お知らせ • Oct 01+ 3 more updatesAmbu A/S to Report Q3, 2023 Results on Aug 31, 2023Ambu A/S announced that they will report Q3, 2023 results on Aug 31, 2023Buying Opportunity • Sep 17Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €11.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 21%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 74% in the next 2 years.Reported Earnings • Aug 26Third quarter 2022 earnings released: EPS: kr.0.11 (vs kr.0.24 in 3Q 2021)Third quarter 2022 results: EPS: kr.0.11 (down from kr.0.24 in 3Q 2021). Revenue: kr.1.13b (up 16% from 3Q 2021). Net income: kr.28.0m (down 55% from 3Q 2021). Profit margin: 2.5% (down from 6.4% in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €9.30, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €9.36, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years.お知らせ • May 20+ 1 more updateAmbu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22Ambu A/S reaffirmed earnings guidance for the fiscal year 2021/22. For the year, the company expects organic growth of positive 13%+ and EBIT margin 5%+.Reported Earnings • May 06Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr.1.12b (up 12% from 2Q 2021). Net income: kr.175.0m (up 84% from 2Q 2021). Profit margin: 16% (up from 9.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 11% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 09First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: kr.0.08 (down from kr.0.37 in 1Q 2021). Revenue: kr.1.03b (up 1.8% from 1Q 2021). Net income: kr.20.0m (down 78% from 1Q 2021). Profit margin: 1.9% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.お知らせ • Feb 09Ambu A/S Revises Revenue Guidance for the Fiscal 2022Ambu A/S revised revenue guidance for the fiscal 2022. The outlook for organic growth is revised from 15% - 19% to 15% (15% or higher).お知らせ • Feb 05Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display UnitAmbu announced the 510(k) regulatory clearance of the Ambu® aScope™ Gastro and Ambu® aBox™ 2 in the United States. aScope Gastro is company's first sterile single-use gastroscope and includes new advanced imaging and design features in a combined solution with next-generation display and processor technology. With HD capabilities, the aBox 2 will set a new benchmark in terms of image quality and will be at the centre of company’s endoscopy ecosystem. With the launch of aScope Gastro, the company enters the gastroscopy segment, where 20 million procedures take place annually with reusable endoscope systems. The advanced technology, portability, and cost-effectiveness of company solution address the current limitations of reusable endoscopes, and it will be an attractive choice for customers looking to perform gastroscopies across a wide range of care settings (including endoscopy unit, OR, ICU, ER, ASC). Furthermore, the aScope Gastro will support healthcare systems in their efforts to reduce waiting lists and overcome staff shortages, which have been accentuated since the start of the COVID-19 pandemic. Finally, the sterile offering provides a solution to the growing cross-contamination risks, especially for vulnerable patients. Expanding Ambu’s presence in GI: Together with the launch of the aScope™ Duodeno 1.5, the aScope Gastro represents the next step in company expansion into the GI segment. They will be followed by the next generation single-use duodenoscope (aScope Duodeno 2.0), a colonoscope and a cholangioscope, giving company the most comprehensive single-use portfolio in GI.Upcoming Dividend • Dec 08Upcoming dividend of kr.0.29 per shareEligible shareholders must have bought the stock before 15 December 2021. Payment date: 17 December 2021. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (0.8%).Reported Earnings • Nov 12Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: kr.4.01b (up 13% from FY 2020). Net income: kr.247.0m (up 2.5% from FY 2020). Profit margin: 6.2% (down from 6.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.Board Change • Nov 09Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Vice-Chairman of the Board Christian Sagild was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.株主還元547ADE Medical EquipmentDE 市場7D8.7%2.8%4.3%1Y-33.6%-26.2%2.9%株主還元を見る業界別リターン: 547A過去 1 年間で-26.2 % の収益を上げたGerman Medical Equipment業界を下回りました。リターン対市場: 547Aは、過去 1 年間で2.9 % のリターンを上げたGerman市場を下回りました。価格変動Is 547A's price volatile compared to industry and market?547A volatility547A Average Weekly Movement5.4%Medical Equipment Industry Average Movement6.0%Market Average Movement5.6%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.7%安定した株価: 547A 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 547Aの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19375,200Britt Jensenwww.ambu.com医療技術会社であるAmbu A/S社は、世界中の病院、診療所、救護所向けに医療機器を開発、製造、販売している。同社は麻酔、患者モニタリング、診断製品を提供している。また、気管支鏡、鼻喉頭鏡、十二指腸鏡、胃カメラ、膀胱鏡、ディスプレイユニットなどの内視鏡製品、EEGやEMG電極、EMGガイド注射、術中モニタリング製品などの神経学製品も提供している。また、心臓病学製品、気管支鏡、ビデオ喉頭鏡、ダブルおよびシングルルーメンチューブ、気管支内ブロッカー、喉頭マスクおよびフェイスマスク、呼吸バッグ、蘇生器などの気道管理および麻酔製品も提供している。さらに、救急カラー、蘇生器、ビデオ喉頭鏡、訓練用マネキンも提供している。アンビューA/Sは1937年に設立され、デンマークのバレラップに本社を置いている。もっと見るAmbu A/S 基礎のまとめAmbu の収益と売上を時価総額と比較するとどうか。547A 基礎統計学時価総額€2.36b収益（TTM）€63.81m売上高(TTM)€816.58m36.9xPER（株価収益率2.9xP/Sレシオ547A は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計547A 損益計算書（TTM）収益DKK 6.10b売上原価DKK 2.44b売上総利益DKK 3.66bその他の費用DKK 3.18b収益DKK 477.00m直近の収益報告Mar 31, 2026次回決算日Aug 26, 2026一株当たり利益（EPS）1.81グロス・マージン59.98%純利益率7.81%有利子負債／自己資本比率0.3%547A の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.6%現在の配当利回り23%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 15:03終値2026/07/06 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ambu A/S 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関null nullABG Sundal CollierMichael HealyBerenbergSusannah LudwigBernstein11 その他のアナリストを表示
お知らせ • Nov 07Ambu A/S announces Annual dividend, payable on December 08, 2025Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025.
お知らせ • Oct 01Ambu A/S, Annual General Meeting, Dec 02, 2026Ambu A/S, Annual General Meeting, Dec 02, 2026.
お知らせ • Sep 30+ 3 more updatesAmbu A/S to Report Q1, 2026 Results on Feb 04, 2026Ambu A/S announced that they will report Q1, 2026 results on Feb 04, 2026
お知らせ • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.
お知らせ • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).
お知らせ • Nov 08Ambu A/S Proposes DividendThe Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year.
お知らせ • Nov 07Ambu A/S announces Annual dividend, payable on December 08, 2025Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025.
お知らせ • Oct 01Ambu A/S, Annual General Meeting, Dec 02, 2026Ambu A/S, Annual General Meeting, Dec 02, 2026.
お知らせ • Sep 30+ 3 more updatesAmbu A/S to Report Q1, 2026 Results on Feb 04, 2026Ambu A/S announced that they will report Q1, 2026 results on Feb 04, 2026
お知らせ • Aug 22Ambu A/S Revises Financial Guidance for the Year 2024/25Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%.
お知らせ • Jan 10Ambu A/S Raises Financial Guidance for the Year 2024/25Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%).
お知らせ • Nov 08Ambu A/S Proposes DividendThe Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year.
Reported Earnings • Nov 06Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023)Full year 2024 results: EPS: kr.0.88 (up from kr.0.65 in FY 2023). Revenue: kr.5.39b (up 13% from FY 2023). Net income: kr.235.0m (up 40% from FY 2023). Profit margin: 4.4% (up from 3.5% in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Oct 01+ 3 more updatesAmbu A/S, Annual General Meeting, Dec 03, 2025Ambu A/S, Annual General Meeting, Dec 03, 2025.
お知らせ • Sep 30Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025Ambu A/S announced that they will report Q1, 2025 results on Jan 30, 2025
Reported Earnings • Sep 01Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023)Third quarter 2024 results: EPS: kr.0.50 (up from kr.0.19 in 3Q 2023). Revenue: kr.1.38b (up 16% from 3Q 2023). Net income: kr.134.0m (up 163% from 3Q 2023). Profit margin: 9.7% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Reported Earnings • May 15Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023)Second quarter 2024 results: EPS: kr.0.54 (up from kr.0.06 in 2Q 2023). Revenue: kr.1.37b (up 15% from 2Q 2023). Net income: kr.144.0m (up kr.129.0m from 2Q 2023). Profit margin: 11% (up from 1.3% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year.
Reported Earnings • Jan 31First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: kr.1.25b (up 11% from 1Q 2023). Net income: kr.92.0m (up 318% from 1Q 2023). Profit margin: 7.3% (up from 1.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Jan 30+ 1 more updateAmbu A/S Maintains Earnings Guidance for the Full-Year 2023/24Ambu A/S maintained earnings guidance for the Full-Year 2023/24. For the period,company expects Organic revenue growth of 7%-10%, EBIT margin before special items of 8%-10%.
お知らせ • Dec 14Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of DirectorsAmbu A/S at its Annual General Meeting held on December 13, 2023, elected Shacey Petrovic as Vice Chair of the Board of Directors.
お知らせ • Nov 18Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of DirectorsAmbu A/S at the Annual General Meeting to be held on 13 December 2023 Henrik Ehlers Wulff has decided not to run for re-election for Board of Directors.
お知らせ • Nov 09Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23.
お知らせ • Oct 12+ 1 more updateAmbu A/S Appoints Henrik Skak Bender as Member of the Executive Management, Effective 1 January 2024Ambu A/S has appointed Henrik Skak Bender as the company’s new Chief Financial Officer and member of the Executive Management, effective 1 January 2024. Henrik succeeds Thomas Frederik Schmidt, who will step down, effective 31 December 2023. During the past 20 years, Henrik has worked at leading international companies, such as was Audiology, Urban Partners, McKinsey & Co and A.P. Moller-Maersk. At the hearing aid company, was Audiology, he served as CFO and Head of Integration, leading the finance, IT, legal and procurement functions. Prior to that, he served as CFO at Widex, where he was responsible for developing and executing the company’s growth and transformation strategy, together with the rest of the management team. Most recently, Henrik joins from the asset management company, Urban Partners, where he serves as a member of the executive management, leading the company to grow from a Nordic player with EUR 6bn in assets under management in 2020 to a Northern European player with EUR +20bn in assets under management. At Urban Partners, Henrik held a position as Partner and COO, where he focused on driving and scaling a wide range of functions, including Investor Relations, Finance, IT and Sustainability.
お知らせ • Sep 30+ 4 more updatesAmbu A/S to Report Q2, 2024 Results on May 14, 2024Ambu A/S announced that they will report Q2, 2024 results on May 14, 2024
お知らせ • Sep 01+ 1 more updateAmbu A/S Narrows Earnings Guidance for the Full-Year 2022/23Ambu A/S narrowed earnings guidance for the full-year 2022/23. For the year, the company expected organic revenue growth guidance to 6%-8%, previously 5%-8%; EBIT margin before special items: 5-6% (maintained as per 10 July 2023).
Reported Earnings • Sep 01Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr.1.20b (up 5.9% from 3Q 2022). Net income: kr.51.0m (up 82% from 3Q 2022). Profit margin: 4.3% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Jul 12Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%).
Reported Earnings • May 03Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr.1.19b (up 6.0% from 2Q 2022). Net income: kr.15.0m (down 91% from 2Q 2022). Profit margin: 1.3% (down from 16% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year.
Reported Earnings • Feb 08First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022)First quarter 2023 results: EPS: kr.0.09 (up from kr.0.08 in 1Q 2022). Revenue: kr.1.13b (up 9.8% from 1Q 2022). Net income: kr.22.0m (up 10.0% from 1Q 2022). Profit margin: 1.9% (in line with 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 07Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023Ambu A/S provided earnings guidance for the financial year of 2022-2023. For the year, the company expected organic revenue growth is 5% to 8%.
Board Change • Nov 22High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Susanne Larsson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 16Full year 2022 earnings releasedFull year 2022 results: Revenue: kr.4.44b (up 11% from FY 2021). Net income: kr.93.0m (down 62% from FY 2021). Profit margin: 2.1% (down from 6.2% in FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.
お知らせ • Oct 01+ 3 more updatesAmbu A/S to Report Q3, 2023 Results on Aug 31, 2023Ambu A/S announced that they will report Q3, 2023 results on Aug 31, 2023
Buying Opportunity • Sep 17Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be €11.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 21%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 74% in the next 2 years.
Reported Earnings • Aug 26Third quarter 2022 earnings released: EPS: kr.0.11 (vs kr.0.24 in 3Q 2021)Third quarter 2022 results: EPS: kr.0.11 (down from kr.0.24 in 3Q 2021). Revenue: kr.1.13b (up 16% from 3Q 2021). Net income: kr.28.0m (down 55% from 3Q 2021). Profit margin: 2.5% (down from 6.4% in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to €9.30, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €9.36, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years.
お知らせ • May 20+ 1 more updateAmbu A/S Reaffirms Earnings Guidance for the Fiscal Year 2021/22Ambu A/S reaffirmed earnings guidance for the fiscal year 2021/22. For the year, the company expects organic growth of positive 13%+ and EBIT margin 5%+.
Reported Earnings • May 06Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr.1.12b (up 12% from 2Q 2021). Net income: kr.175.0m (up 84% from 2Q 2021). Profit margin: 16% (up from 9.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 11% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 09First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: EPS: kr.0.08 (down from kr.0.37 in 1Q 2021). Revenue: kr.1.03b (up 1.8% from 1Q 2021). Net income: kr.20.0m (down 78% from 1Q 2021). Profit margin: 1.9% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 09Ambu A/S Revises Revenue Guidance for the Fiscal 2022Ambu A/S revised revenue guidance for the fiscal 2022. The outlook for organic growth is revised from 15% - 19% to 15% (15% or higher).
お知らせ • Feb 05Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display UnitAmbu announced the 510(k) regulatory clearance of the Ambu® aScope™ Gastro and Ambu® aBox™ 2 in the United States. aScope Gastro is company's first sterile single-use gastroscope and includes new advanced imaging and design features in a combined solution with next-generation display and processor technology. With HD capabilities, the aBox 2 will set a new benchmark in terms of image quality and will be at the centre of company’s endoscopy ecosystem. With the launch of aScope Gastro, the company enters the gastroscopy segment, where 20 million procedures take place annually with reusable endoscope systems. The advanced technology, portability, and cost-effectiveness of company solution address the current limitations of reusable endoscopes, and it will be an attractive choice for customers looking to perform gastroscopies across a wide range of care settings (including endoscopy unit, OR, ICU, ER, ASC). Furthermore, the aScope Gastro will support healthcare systems in their efforts to reduce waiting lists and overcome staff shortages, which have been accentuated since the start of the COVID-19 pandemic. Finally, the sterile offering provides a solution to the growing cross-contamination risks, especially for vulnerable patients. Expanding Ambu’s presence in GI: Together with the launch of the aScope™ Duodeno 1.5, the aScope Gastro represents the next step in company expansion into the GI segment. They will be followed by the next generation single-use duodenoscope (aScope Duodeno 2.0), a colonoscope and a cholangioscope, giving company the most comprehensive single-use portfolio in GI.
Upcoming Dividend • Dec 08Upcoming dividend of kr.0.29 per shareEligible shareholders must have bought the stock before 15 December 2021. Payment date: 17 December 2021. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (0.8%).
Reported Earnings • Nov 12Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: kr.4.01b (up 13% from FY 2020). Net income: kr.247.0m (up 2.5% from FY 2020). Profit margin: 6.2% (down from 6.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings.
Board Change • Nov 09Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Vice-Chairman of the Board Christian Sagild was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
